Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score a data driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
OKYO Pharma Limited Sponsored ADR ( (OKYO) ) has shared an update.
On January 22, 2025, OKYO Pharma Limited announced it received $1.4 million in non-dilutive funding, enhancing its ability to advance its innovative pipeline without impacting shareholder value. The funding will be allocated to research and development, focusing on its lead program, OK-101, aimed at treating NCP, a major unmet medical need. This financial boost supports OKYO’s mission to develop groundbreaking treatments for ophthalmic diseases, maintaining fiscal responsibility while pursuing transformative therapies.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED). The company is committed to discovering and developing novel molecules to address these ophthalmic conditions, with its shares listed on the NASDAQ Capital Market.
YTD Price Performance: -7.96%
Average Trading Volume: 85,142
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $35.24M
See more data about OKYO stock on TipRanks’ Stock Analysis page.
